China SXT Pharmaceuticals closes $12M registered direct offering

China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) has closed a $12 million registered direct offering, with Univest Securities, LLC acting as sole placement agent, according to a press release.

Under the terms of the offering, the company sold 8,000,000 Class A ordinary shares at a purchase price of $1.50 per share to institutional investors, with the option to issue pre-funded warrants in lieu of shares.

The company also issued 8,000,000 warrants to the same investors at an exercise price of $1.50 per share. The warrants are immediately exercisable upon issuance and carry a one-year term. Each warrant includes a zero cash exercise option allowing the holder to acquire up to nine Class A shares.

The offering was made pursuant to a shelf registration statement on Form F-3 previously filed by the company and declared effective by the U.S. Securities and Exchange Commission on December 1, 2025.

China SXT Pharmaceuticals is a China-based company focused on the research, development, manufacture, and sales of traditional Chinese medicine pieces, headquartered in Taizhou City, Jiangsu Province.

You May Also Be Interested In

• Fortune Favor to merge with Quantumsphere in $600M SPAC deal
• China SXT Pharmaceuticals plans $12M direct offering at $1.50 per share
• CrowdStrike urges stockholders to reject Tutanota mini-tender offer